HKEX: 2228
Next Day Disclosure Return
View original source (HKEXnews)
Earlier from Xtalpi
- XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
- XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
- XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
- XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target